重型新型冠状病毒肺炎合并肝素抵抗2例
本文报告2021年11月连云港市第一人民医院医疗队在ICU收治的2例重型COVID-19合并肝素抵抗患者。2例均接受机械通气,其中1例接受ECMO支持;均在常规剂量抗凝治疗下出现下肢深静脉血栓及肝素抵抗现象,普通肝素最大日剂量超过35 000 U(最高达43 200 U),2例均未达到抗凝治疗标准、病程延长。随后给予阿加曲班0.4 μg×kg-1×min-1联合抗凝治疗,接受ECMO者的活化部分凝血活酶时间(APTT)维持在55-60秒、活化凝血时间(ACT)维持在180-200秒。经ECMO支持或后续序贯机械通气后,2例均康复出院,深静脉血栓也得到有效控制。作者认为重型COVID-19治疗过程中常出现肝素抵抗现象,应及时调整抗凝方案。
要点
- 2例重型COVID-19患者在常规剂量抗凝治疗下均出现下肢深静脉血栓及肝素抵抗现象。
- 普通肝素最大日剂量超过35 000 U(最高达43 200 U),2例均未达到抗凝治疗标准,病程延长。
- 改用阿加曲班0.4 μg×kg-1×min-1联合抗凝治疗后,接受ECMO者APTT维持在55-60秒、ACT维持在180-200秒。
- 经ECMO支持或后续序贯机械通气后2例均康复出院,深静脉血栓得到有效控制。
- 作者认为重型COVID-19治疗过程中常出现肝素抵抗现象,应及时调整抗凝方案。
适用人群与场景
- 2021年11月在连云港市指定医院ICU收治的2例重型COVID-19患者,均接受机械通气,其中1例接受ECMO支持。
诊断标准与关键阈值
- 肝素抵抗现象:2例在常规剂量抗凝治疗下出现下肢深静脉血栓,普通肝素最大日剂量超过35 000 U(最高达43 200 U)仍未达到抗凝治疗标准。
- 抗凝目标:接受ECMO者APTT维持在55-60秒、ACT维持在180-200秒。
处置流程与药物剂量
- 常规剂量抗凝治疗下出现肝素抵抗、未达抗凝标准时,及时调整抗凝方案(作者结论)。
- 给予阿加曲班0.4 μg×kg-1×min-1联合抗凝治疗,接受ECMO者APTT维持在55-60秒、ACT维持在180-200秒。
- 继续ECMO支持或后续序贯机械通气。
红旗征与不能漏的情况
- 常规剂量抗凝治疗下出现下肢深静脉血栓及肝素抵抗现象,需及时调整抗凝方案。
研究设计与关键结果
- 2例重型COVID-19患者均接受机械通气,1例接受ECMO支持;均在常规剂量抗凝治疗下并发下肢深静脉血栓及肝素抵抗现象。
- 普通肝素最大日剂量超过35 000 U(最高达43 200 U),2例均未达到抗凝治疗标准,病程延长。
- 给予阿加曲班0.4 μg×kg-1×min-1联合抗凝治疗后,接受ECMO者APTT维持在55-60秒、ACT维持在180-200秒。
- 经ECMO支持或后续序贯机械通气后2例均康复出院,深静脉血栓得到有效控制。
证据类型、等级与局限
- 证据类型:病例报告(2例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为重型COVID-19治疗过程中常出现肝素抵抗现象,应及时调整抗凝方案。
- 作者认为联合阿加曲班的抗凝效果明确。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the diagnosis process and treatment experience of severe coronavirus disease 2019 (COVID-19) patients with heparin resistance (HR).
METHODS: The medical team of the First People's Hospital of Lianyungang admitted 2 severe COVID-19 patients with HR in intensive care unit (ICU) during their support to the designated hospital for the treatment of COVID-19 patients in Lianyungang City in November 2021. The clinical features, laboratory examinations, imaging features, treatment and prognosis of the two patients were analyzed.
RESULTS: Both severe COVID-19 patients received mechanical ventilation, 1 patient was treated with extracorporeal membrane oxygenation (ECMO) support. Both patients were complicated with lower extremity deep venous thrombosis and HR phenomenon under routine dose anticoagulant therapy. The maximum daily dose of unfractionated heparin exceeded 35 000 U (up to 43 200 U), the 2 patients failed to meet the standard of anticoagulation treatment, and the course of disease was prolonged. After that, argatroban was given 0.4 μg×kg-1×min-1 combined with anticoagulant therapy, the activated partial thromboplastin time (APTT) of patients undergoing ECMO could be maintained at 55-60 seconds and the activated coagulation time (ACT) of them could be maintained at 180-200 seconds. After ECMO support or later sequential mechanical ventilation, both patients recovered and were discharged, and deep venous thrombosis was also effectively controlled.
CONCLUSIONS: HR phenomenon often occurs during the treatment of severe COVID-19 patients, the anticoagulation regimen should be adjusted in time, and the anticoagulation effect combined with argatroban is clear.
参考来源
- Xie Y, Luo J, Li J, et al. [Critical coronavirus disease 2019 complicated with heparin resistance in 2 patients]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 35728853. doi:10.3760/cma.j.cn121430-20220106-00012
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。